Laurus Labs Limited (LAURUSLABS): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Laurus Labs Limited, explained in plain English.

• ▪Laurus Labs Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪LAURUSLABS closed at ₹2,383.10 on 30 October 2026.
• ▪Over the past year the shares are up 145.6%, trading between ₹917.95 and ₹2,244.00.
• ▪Reported fundamentals show a net margin of 15.04%, debt to equity of 46.37.
• ▪Our transparent MaxGrade checklist scores it B (66/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 29.93% with a maximum drawdown of -16.27% and a beta of 0.77 against NIFTY 50.
• ▪Recent coverage: Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
• ▪Recent coverage: Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
• ▪Recent coverage: Bharti Airtel, MCX, Laurus Labs look bullish on charts: Chandan Taparia

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Figures from the current session. Market open.